

September 25, 2019

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

‘Update on Ranitidine tablets’

Thanks & Regards,

For Strides Pharma Science Limited



**Manjula Ramamurthy
Company Secretary**



Encl: As Above

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

Update on Ranitidine tablets

- Strides has approval for Rx and OTC Ranitidine tablets for the US market and is only commercializing the Rx product currently.
- The USFDA has learned that some ranitidine products contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is also found in water and foods, including meats, dairy products, and vegetables and is not expected to cause harm when ingested in very low levels.
- USFDA is not calling for individuals to stop taking ranitidine at this time. The agency is examining the levels of NDMA in ranitidine and is evaluating any possible risks to patients.
- Basis a Citizen petition, the USFDA is now reaching out to all formulation companies to perform tests to evaluate presence of NDMA in the product.
- Strides has also received an Information Request (IR) today from USFDA to provide test data in next 30 days. The company is in the process of responding to the IR comprehensively. Further updates on the product will be provided post completion of the requisite tests.
- Ranitidine tablets is amongst the top 5 products sold by the company in the USA.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

Strides**Badree Komandur**Executive Director - Finance
+91 80 6784 0747**Investor Relations:****Kannan. N:** +91 98450 54745**PR Consultancy**

Fortuna PR

K Srinivas Reddy: +91 90005 27213
srinivas@fortunapr.comK Priya: +91 95354 25418
priya@fortunapr.com

Vikesh Kumar: +91 80 6784 0827

Sandeep Baid: +91 80 6784 0791

Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta
Road, Bangalore – 560 076